Intravenous immunoglobulin alleviates Japanese encephalitis virus-induced peripheral neuropathy by inhibiting the ASM/ceramide pathway
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112083 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Na Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, Ningxia Medical University, Yinchuan, Ningxia, China; Neurology Center, General Hospital of Ningxia Medical University, …. Hauptthemen laut MEDLINE: Ceramides, Encephalitis, Japanese, Immunoglobulins, Intravenous, Peripheral Nervous System Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
Japanese encephalitis virus (JEV) infection is considered a global public health emergency. Severe peripheral neuropathy caused by JEV infection has increased disability and mortality rates in recent years. Because there are very few therapeutic options for JEV infection, prompt investigations of the ability of clinically safe, efficacious and globally available drugs to inhibit JEV infection and ameliorate peripheral neuropathy are urgently needed. In this study, we found that high doses of intravenous immunoglobulin, a function inhibitor of acid sphingomyelinase (FIASMA), inhibited acid sphingomyelinase (ASM) and ceramide activity in the serum and sciatic nerve of JEV-infected rats, reduced disease severity, reversed electrophysiological and histological abnormalities, significantly reduced circulating proinflammatory cytokine levels, inhibited Th1 and Th17 cell proliferation, and suppressed the infiltration of inflammatory CD4 + cells into the sciatic nerve. It also maintained the peripheral nerve-blood barrier without causing severe clinical side effects. In terms of the potential mechanisms, ASM was found to participate in immune cell differentiation and to activate immune cells, thereby exerting proinflammatory effects. Therefore, immunoglobulin is a FIASMA that reduces abnormal immune responses and thus targets the ASM/ceramide system to treat peripheral neuropathy caused by JEV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Clinical Medicine, Ningxia Medical University, Yinchuan, Ningxia, China; Neurology Center, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
- School of Clinical Medicine, Ningxia Medical University, Yinchuan, Ningxia, China.
- Neurology Center, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
- Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, Ningxia Medical University, Yinchuan, Ningxia, China.
- School of Clinical Medicine, Ningxia Medical University, Yinchuan, Ningxia, China; Diagnosis and Treatment Engineering Technology Research Center of Nervous System Diseases of Ningxia Hui Autonomous Region, General Hosp…
Zitieren
APA
Zhang, N., Wang, G., Yang, L., Zhang, J., Yuan, Y., Ma, L., & Wang, Z. (2024). Intravenous immunoglobulin alleviates Japanese encephalitis virus-induced peripheral neuropathy by inhibiting the ASM/ceramide pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112083
Vancouver
Zhang N, Wang G, Yang L, Zhang J, Yuan Y, Ma L, et al. Intravenous immunoglobulin alleviates Japanese encephalitis virus-induced peripheral neuropathy by inhibiting the ASM/ceramide pathway. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112083
BibTeX
@article{Zhang2024,
author = {Zhang, Na and Wang, Guowei and Yang, Liping and Zhang, Jinyuan and Yuan, YanPing and Ma, Lijun and Wang, Zhenhai},
title = {Intravenous immunoglobulin alleviates Japanese encephalitis virus-induced peripheral neuropathy by inhibiting the ASM/ceramide pathway},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112083}
}
EUVIMED